Radicle RestTM VGI: A Study Assessing the Impact of Health and Wellness Products Gene III® L-Ergothioneine Capsules and Gene III® L-Ergothioneine on Sleep and Related Health Outcomes
Radicle RestTM VGI: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products Gene III® L-Ergothioneine Capsules and Gene III® L-Ergothioneine on Sleep and Related Health Outcomes
Radicle RestTM VGI: A randomized, double-blind, placebo- controlled study assessing the impact of health and wellness Gene III® L-Ergothioneine Capsules and Gene III® L-Ergothioneine products on sleep and related health outcomes.
研究概览
详细说明
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants will (1) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, and (2) express acceptance in taking a product and not knowing its formulation until the end of the study.
Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.
Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at enrollment and throughout the active period of study product usage. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
California
-
Del Mar、California、美国、92014-2605
- Radicle Science Inc.
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
3.1 Inclusion
Participants must meet all the following criteria:
-
Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
- Assigned sex at birth will determine sex-specific recruitment and PROs (male vs female) employed, when needed
-
Resides in the United States
-
Has the opportunity for at least 30% improvement in their primary health outcome
-
Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
3.2 Exclusion
Individuals who report any of the following during screening may be excluded from participation:
-
Report being pregnant, trying to become pregnant, or breastfeeding
-
Unable to provide a valid US shipping address and mobile phone number
-
Reports current enrollment in another clinical trial
-
Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
-
Unable to read and understand English at a 7th grade level
-
Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
-
Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
- NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
-
Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
- Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
-
Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk
-
Lack of reliable daily access to the internet
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Active Rest Product 1
Active Rest Product 1 |
Participants will use their Active Rest Product 1 as directed for a period of 6 weeks |
|
安慰剂比较:Placebo Rest Control
Placebo Rest Control |
Participants will use their Placebo Rest Control as directed for a period of 6 weeks |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in sleep
大体时间:7 weeks
|
Change in sleep: Difference in rates of change over time in sleep score as assessed by PROMIS Sleep Disturbance 8A (scale 8-40; where higher scores correspond to higher levels of sleep disturbance) |
7 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in sleep-related impairment
大体时间:7 weeks
|
Change in sleep-related impairment: Difference between rates of change over time in sleep score as assessed by PROMIS Sleep-Related Impairment 8a (scale 8-40; where the higher scores correspond to worse sleep) |
7 weeks
|
|
Change in mood (emotional distress-depression)
大体时间:7 weeks
|
Change in mood (emotional distress-depression): Difference in rates of change over time in emotional distress score as assessed by PROMIS Emotional Distress- Depression 8A (scale 8-40; with higher scores corresponding to greater levels of emotional distress) |
7 weeks
|
|
Change in fatigue
大体时间:7 weeks
|
Change in fatigue: Difference in rates of change over time in fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 8A (scale 8-40; where higher scores correspond to more severe fatigue) |
7 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Minimal clinically important difference (MCID) in sleep
大体时间:7 weeks
|
Minimal clinically important difference (MCID) in sleep: Likelihood of experiencing minimal clinically important difference in sleep score as assessed by PROMIS Sleep Disturbance 8A (scale 8-40; where higher scores correspond to higher levels of sleep disturbance) |
7 weeks
|
|
Minimal clinically important difference (MCID) in mood (emotional distress-depression)
大体时间:7 weeks
|
Minimal clinically important difference (MCID) in mood (emotional distress-depression): Likelihood of experiencing minimal clinically important difference in mood score as assessed by PROMIS Emotional Distress- Depression 8A (scale 8-40; with higher scores corresponding to greater levels of emotional distress) |
7 weeks
|
|
Minimal clinically important difference (MCID) in sleep
大体时间:7 weeks
|
Minimal clinically important difference (MCID) in sleep: Likelihood of experiencing minimal clinically important difference in sleep score, as measured by PROMIS Sleep-Related Impairment 8a (scale 8-40; where the higher scores correspond to worse sleep) |
7 weeks
|
|
Change in cognitive function
大体时间:7 weeks
|
Change in cognitive function: Difference in rates of change over time in cognitive function score as assessed by PROMIS Cognitive Function 8A (scale 8-40; where lower scores correspond to worse cognitive function) |
7 weeks
|
|
Minimal clinically important difference (MCID) in cognitive function
大体时间:7 weeks
|
Minimal clinically important difference (MCID) in cognitive function: Likelihood of experiencing minimal clinically important difference in cognitive function score as assessed by PROMIS Cognitive Function 8A (scale 8-40; where lower scores correspond to worse cognitive function) |
7 weeks
|
|
Change in feelings of anxiety
大体时间:7 weeks
|
Change in feelings of anxiety: Difference between rates of change over time in feelings of anxiety score as assessed by PROMIS Anxiety 8A (scale 8-40; with higher scores corresponding to more severe anxiety) |
7 weeks
|
|
Minimal clinically important difference (MCID) in feelings of anxiety
大体时间:7 weeks
|
Minimal clinically important difference (MCID) in feelings of anxiety: Likelihood of experiencing minimal clinically important difference in feelings of anxiety score as assessed by PROMIS Anxiety 8A (scale 8-40; with higher scores corresponding to more severe anxiety) |
7 weeks
|
合作者和调查者
调查人员
- 首席研究员:Susan Hewlings、Radicle Science
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.